Citigroup’s Vigil Neuroscience VIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-3,500
| Closed | -$27.8K | – | 6342 |
|
|
2025
Q2 | $27.8K | Buy |
+3,500
| New | +$15.7K | ﹤0.01% | 4996 |
|
|
2025
Q1 | – | Sell |
-18,130
| Closed | -$30.8K | – | 5995 |
|
|
2024
Q4 | $30.8K | Sell |
18,130
-30,253
| -63% | -$89.3K | ﹤0.01% | 5200 |
|
|
2024
Q3 | $165K | Buy |
48,383
+45,972
| +1,907% | +$170K | ﹤0.01% | 4483 |
|
|
2024
Q2 | $9.64K | Sell |
2,411
-64,899
| -96% | -$222K | ﹤0.01% | 5152 |
|
|
2024
Q1 | $230K | Buy |
67,310
+658
| +1% | +$2.05K | ﹤0.01% | 3950 |
|
|
2023
Q4 | $225K | Buy |
66,652
+2,349
| +4% | +$12.1K | ﹤0.01% | 3856 |
|
|
2023
Q3 | $347K | Sell |
64,303
-4,774
| -7% | -$33K | ﹤0.01% | 3327 |
|
|
2023
Q2 | $649K | Sell |
69,077
-22,321
| -24% | -$211K | ﹤0.01% | 3179 |
|
|
2023
Q1 | $895K | Sell |
91,398
-2,529
| -3% | -$28.4K | ﹤0.01% | 2651 |
|
|
2022
Q4 | $1.17M | Buy |
93,927
+26,272
| +39% | +$322K | ﹤0.01% | 2464 |
|
|
2022
Q3 | $616K | Buy |
67,655
+2,592
| +4% | +$19K | ﹤0.01% | 3087 |
|
|
2022
Q2 | $168K | Buy |
65,063
+969
| +2% | +$3.83K | ﹤0.01% | 3945 |
|
|
2022
Q1 | $451K | Buy |
+64,094
| New | +$846K | ﹤0.01% | 3592 |
|
Other funds holding VIGL
Citigroup's VIGL Position: Q3 2025 in Review
Citigroup sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 3,500 shares — an estimated $27.8K sold.
Citigroup first reported a position in VIGL in Q1 2022 and held it in 13 quarters. The position peaked at $1.17M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.
- Citigroup reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
- Citigroup sold 3,500 Vigil Neuroscience shares in Q3 2025, an estimated $27.8K.
- Citigroup first reported a position in Vigil Neuroscience in Q1 2022 and held it in 13 quarters.
- Citigroup's Vigil Neuroscience position peaked at $1.17M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.
Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.